US Patent 8,530,485 Scope and Claims Analysis: Sustained-Release Oral Composition for 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile
Executive summary: US 8,530,485 is an oral pharmaceutical formulation patent focused on sustained-release delivery of a specific small-molecule compound (and salts), including stereospecific coverage for the (3R) enantiomer, plus unit-dose embodiments (tablet or capsule), and optional enteric coating. The claim set is broad at the “composition suitable for oral administration and sustained release” level, then narrows through enantiomer selection and concrete dosage-form structure. The patent’s enforceable scope is likely concentrated in commercial products that use the same active and that implement sustained-release oral technology through carriers and dosage forms falling within the claim language (tablet/capsule, optional enteric coating, and specified quantitative range for dose).
Because the input provides only the claims and not the patent’s specification, dependent-claim numbering context, prosecution history, priority dates, listed embodiments, or the full claim set from the issued patent, the scope and “patent landscape” below is limited to what can be derived from the provided claims alone.
What is US 8,530,485 protecting: sustained-release oral composition claims for the specified propanenitrile?
Short answer: The patent protects an oral pharmaceutical composition containing a particular compound (or salt) and a pharmaceutically acceptable carrier, where the composition is “suitable for oral administration and for providing sustained release.” It also protects narrower embodiments covering the (3R) enantiomer, unit dosage forms (tablet or capsule), optional enteric coating, and specific dose and excipient embodiments.
Core independent claim: composition for oral sustained release
Claim 1 recites:
- A pharmaceutical composition
- Comprising:
- the compound: 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile (or pharmaceutically acceptable salt)
- a pharmaceutically acceptable carrier
- A functional limitation:
- composition is suitable for oral administration
- providing sustained release of the compound (or salt)
Legal scope implications:
- The claim is formulation-first. It does not claim a manufacturing method, a device, or a specific sustained-release mechanism (matrix vs. coating vs. bead vs. osmotic). Unless the specification limits “sustained release,” infringement arguments can extend across typical sustained-release oral dosage technologies, provided the accused product meets the “sustained release” functionality.
- “Suitable for oral administration” is a low barrier; most oral drug products will satisfy it.
- “Sustained release” is a classic functional limitation that typically becomes a technical battleground: how the product releases over time, dissolution profile parameters, and whether the accused formulation is “sustained” vs. immediate/extended.
What compounds are covered?
- The compound name is specific and appears to be a single chemical entity (plus salts).
- The salt language is broad: any pharmaceutically acceptable salt that satisfies the carrier and sustained-release requirements.
How broad are the claim terms “sustained release,” “pharmaceutically acceptable carrier,” and “pharmaceutically acceptable salt”?
Short answer: The breadth hinges on whether the patent’s specification defines sustained-release characteristics and supported salt/counterion lists. Based only on claim language, “sustained release” and “carrier” are likely construed broadly as long as they are pharmaceutically acceptable and achieve a sustained-release profile.
“Sustained release”: functional limitation with technical scope
Claim 1 does not specify:
- target release duration (eg, 8, 12, 24 hours)
- Cmax/Tmax constraints
- dissolution specifications (Q values at timepoints)
- method of achieving sustained release
This creates two consequences:
- Coverage may be technology-agnostic across sustained-release systems, if they are characterized as sustained-release in relevant pharmacopeial/dissolution testing.
- Validity and prosecution-history issues can matter if “sustained release” was used to distinguish prior art without specifying parameters. The narrower the specification’s definition, the more likely “sustained release” will be treated as limited.
“Pharmaceutically acceptable carrier”: broad excipient category
Claim 1 is not limited to specific excipients. Dependent claims then enumerate common excipients in a nonexclusive “one or more excipients selected from…” list (Claim 8), supporting the idea that the invention is not restricted to a specific polymer or bulking agent.
“Pharmaceutically acceptable salt”: broad
Claim 1 covers “a pharmaceutically acceptable salt.” That typically expands coverage to multiple salt forms unless the specification restricts which salts are contemplated.
What patents claims add stereochemical coverage for the (3R) enantiomer in US 8,530,485?
Short answer: Claim 2 limits Claim 1 to compositions where the compound is the (3R) enantiomer (or its salts). This provides separate enforceability against products that use the single (3R) form even if a broader racemate-based formulation might differ.
Enantiomer-specific limitation
- Claim 2 depends on Claim 1 and specifies:
- compound is (3R)-3-cyclopentyl-3-[…]propanenitrile
- or a pharmaceutically acceptable salt
Scope implications:
- Products using a different stereoisomer (eg, racemate, (3S), or other stereochemical mixtures) would not satisfy Claim 2 but could still infringe Claim 1 if they include the claimed “compound” as written and the claim construction treats the name as covering the stereoisomer actually used.
- Practical enforcement depends on how “compound” in Claim 1 is construed: if Claim 1’s compound name is interpreted to include all stereoisomers, Claim 2 adds a narrower subset. If Claim 1 is interpreted to refer to a specific stereoisomer by default, then Claim 2 may be duplicative or further limit the scope.
What dosage forms are covered: unit dosage tablets, capsules, and optional enteric coating?
Short answer: Claims 3-6 cover unit dosage forms in tablet or capsule form, with optional enteric coating in one dependent claim.
Unit dosage form and tablet/capsule pathways
- Claim 3: composition is a unit dosage form
- Claim 4: unit dosage form is a tablet
- Claim 5: unit dosage form is a capsule
- Claim 6: unit dosage form further comprises an enteric coating
Scope implications:
- The independent “composition” claim in Claim 1 could read on non-unit or multi-dose forms, but dependent claims can be used to strengthen enforcement on typical commercial oral presentations.
- Enteric coating suggests the patent expects performance in the gastrointestinal tract, possibly protecting drug release from gastric acid or shifting dissolution to intestinal conditions.
Enforcement angles:
- If a generic/competitor product uses enteric-coated sustained-release tablets or capsules of the same active/salt, Claim 6 is directly relevant.
- If a product uses sustained-release tablets/capsules without enteric coating, Claims 4 or 5 are the closer match.
What dose range and excipient limitations exist in US 8,530,485?
Short answer: The patent includes a dependent claim specifying a broad dose band (5 to 1000 mg) and an excipient list limited to commonly used pharmaceutically acceptable excipients.
Dose amount range
- Claim 7 depends from Claim 2 (the (3R) embodiment) and recites:
- unit dosage form comprises about 5 to about 1000 mg of the compound or salt
Scope implications:
- Many commercial strengths fall within this band for oral small-molecule drugs, so this claim can be practical for infringement.
- “About” adds flexibility; exact percent by weight per unit depends on the product.
Excipients list and microcrystalline cellulose/lactose specificity
- Claim 8 depends from Claim 2 and includes:
- one or more excipients selected from a long list including lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose
- Claim 9 depends from Claim 2 and specifies microcrystalline cellulose
- Claim 10 depends from Claim 2 and specifies lactose
Scope implications:
- Claims 8-10 provide fallback positions against formulations using conventional excipient systems.
- These dependent claims can matter in litigation where the main disputed point is sustained-release design. Even if a defendant argues the formulation uses different excipients, Claims 8-10 provide coverage for products that include these conventional carriers.
What other claim themes appear missing from the provided excerpt (and how does that affect landscape coverage)?
Based on the provided claims alone, the patent appears to focus narrowly on:
- oral sustained-release compositions
- stereochemical specificity (3R)
- unit-dose form (tablet/capsule)
- optional enteric coating
- dose range
- common excipient compositions
Notably absent from the provided claim text:
- explicit formulation mechanics (eg, specific polymer types or ratios)
- explicit sustained-release architecture (matrix vs. coating parameters)
- method-of-manufacture claims
- specific dissolution targets
- specific salt identities (counterions)
This shapes the landscape risk:
- If competitors use the same active/salt but with materially different sustained-release design and excipient choices, infringement could turn on whether the product is still “suitable for sustained release” and whether the dependent claim limitations are met (dose, excipients, enteric coating).
How strong is US 8,530,485 likely to be against generics: what would a Paragraph IV formulation challenge focus on?
Short answer: A generic Paragraph IV challenge to this type of formulation claim typically targets (i) noninfringement on sustained-release functionality and dosage-form differences, and/or (ii) invalidity based on prior art sustained-release oral formulations of the same or obvious analog actives, and/or (iii) lack of written description or enablement if the patent’s specification does not support the breadth of “sustained release” and the broad excipient/salt scope.
Noninfringement theories to expect
- The generic uses a release profile that is not “sustained release” under the patent’s claim construction.
- The generic does not use the (3R) enantiomer where Claim 2 is asserted.
- The generic is not a unit dosage form, or it is not tablet/capsule in asserted dependent claims.
- The generic lacks enteric coating where Claim 6 is asserted.
- The product’s strength is outside “about 5 to about 1000 mg” (less likely).
- Excipient selection differs such that Claims 8-10 are avoided (Claim 1 still may be asserted).
Invalidity theories to expect
- Prior art: sustained-release oral compositions of this active (or its salts) using conventional carriers.
- Obviousness: combining a known active (or salt) with standard sustained-release carriers could be argued.
- Claim indefiniteness: disputes if “sustained release” lacks objective boundaries. Courts usually resolve this through expert testimony and how POS/PSP is interpreted in the record.
What patents and parties are likely in the landscape: how to read the claims as a proxy for competitive positioning?
Short answer: US 8,530,485 is a formulation patent. In most drug development programs, formulation patents cluster around:
- original NCE salt/enantiomer IP
- solid-form IP (polymorphs, hydrates, solvates)
- sustained-release oral formulation IP
- method-of-treatment IP (if any)
With only the claim excerpt, the most actionable landscape inference is the “product design axis” competitors must navigate:
- Use of the exact active compound and the correct salt/enantiomer.
- Achieving a sustained-release profile while potentially designing around specific excipients and coatings.
- Matching unit-dose attributes (tablet/capsule) where dependent claims are asserted.
Practically: a generic looking to design around would attempt to:
- avoid the (3R) composition if Claim 2 is heavily asserted
- avoid enteric coating if Claim 6 is asserted
- avoid listed excipients for Claims 8-10
- or argue the product is not “suitable for sustained release” (functional noninfringement)
What does US 8,530,485 cover across jurisdictions: US claim coverage vs global formulation risk?
Short answer: The patent is a US composition claim. The claim text itself does not determine foreign counterparts, so a global risk assessment depends on whether similar formulation claims were filed in Europe, UK, or other jurisdictions. The enforceability is jurisdiction-specific, but the design-around levers (sustained release functionality, enantiomer, dosage form, coatings, excipients) are conceptually portable.
Key Takeaways
- US 8,530,485 protects an oral sustained-release composition containing a specific propanenitrile compound (or salts) plus a pharmaceutically acceptable carrier.
- Claim strength increases in dependent embodiments for common commercial features: (3R) enantiomer, unit dosage tablets/capsules, and optional enteric coating.
- Dose range (about 5 to 1000 mg) and common excipients (lactose, microcrystalline cellulose, PVP, methyl cellulose, alginates, etc.) provide practical infringement hooks for typical oral solid dosage manufacturing.
- Patent landscape risk for generics likely turns on technical evidence: whether the accused product qualifies as sustained release, and whether it matches asserted dependent limitations (enantiomer, enteric coating, excipients, dosage form, and strength).
FAQs
1) Does US 8,530,485 require a specific sustained-release technology (matrix vs coating)?
No. Claim 1 is technology-agnostic and is framed around the functional outcome of sustained release.
2) What claims are most relevant to a sustained-release tablet without enteric coating?
Claims 1 and 4 (and Claim 2 if (3R) is used). Enteric coating is only in Claim 6.
3) If a competitor uses the racemate rather than the (3R) enantiomer, which claims are avoided?
Claims that depend from Claim 2 (Claims 2-10) are aimed at the (3R) enantiomer embodiment. Claim 1 may still be asserted depending on claim construction of the compound definition.
4) Can excipient substitutions avoid infringement under US 8,530,485?
Excipient substitutions can help avoid dependent excipient-specific claims (Claims 8-10), but they do not, by themselves, avoid Claim 1.
5) What is the most likely dispute point in litigation over US 8,530,485?
The definition and measurement of “sustained release” relative to the accused product’s dissolution and pharmacokinetic release profile.
References
- US Patent 8,530,485 (claims provided in user input).
